melatonin has been researched along with Bone Cancer in 21 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin is recognized as an anti-angiogenic agent, but its function in the tumor microenvironment especially in osteosarcoma remains uncertain." | 7.96 | Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma. ( Anuradha, D; Raghunandhakumar, S; Saravanan, S; Vimalraj, S, 2020) |
| "To evaluate the effects of melatonin (Mel) combined with cis-platinum (DDP) or methotrexate (MTX) on the proliferation of osteosarcoma cell line SaOS-2, and to explore whether Mel combined with DDP or MTX could play a synergistic antitumor effect." | 7.81 | Effects of melatonin combined with Cis-platinum or methotrexate on the proliferation of osteosarcoma cell line SaOS-2. ( Wang, YP; Yang, ZP, 2015) |
| "Although bone cancer is relatively rare, it is a serious disease that often becomes metastatic, leading to an unsatisfactory prognosis." | 7.01 | Potential Mechanisms of Melatonin in Osteosarcoma and Bone-Related Neoplasms: Updated Review. ( Asemi, Z; Dana, PM; Reiter, RJ; Sadoughi, F; Yousefi, B, 2023) |
| "Melatonin treatment significantly downregulated the expression of lncRNA JPX in Saos-2, MG63 and U2OS cells." | 5.62 | Anticancer effects of melatonin via regulating lncRNA JPX-Wnt/β-catenin signalling pathway in human osteosarcoma cells. ( Du, J; Li, B; Li, Y; Zou, J, 2021) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "Melatonin is recognized as an anti-angiogenic agent, but its function in the tumor microenvironment especially in osteosarcoma remains uncertain." | 3.96 | Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma. ( Anuradha, D; Raghunandhakumar, S; Saravanan, S; Vimalraj, S, 2020) |
| "To evaluate the effects of melatonin (Mel) combined with cis-platinum (DDP) or methotrexate (MTX) on the proliferation of osteosarcoma cell line SaOS-2, and to explore whether Mel combined with DDP or MTX could play a synergistic antitumor effect." | 3.81 | Effects of melatonin combined with Cis-platinum or methotrexate on the proliferation of osteosarcoma cell line SaOS-2. ( Wang, YP; Yang, ZP, 2015) |
| "Although bone cancer is relatively rare, it is a serious disease that often becomes metastatic, leading to an unsatisfactory prognosis." | 3.01 | Potential Mechanisms of Melatonin in Osteosarcoma and Bone-Related Neoplasms: Updated Review. ( Asemi, Z; Dana, PM; Reiter, RJ; Sadoughi, F; Yousefi, B, 2023) |
| "Melatonin was given orally at 20 mg/day in the evening for at least 2 months." | 2.70 | Anti-angiogenic activity of melatonin in advanced cancer patients. ( Bucovec, R; Conti, A; Lissoni, P; Maestroni, GJ; Malugani, F; Rovelli, F, 2001) |
| "Melatonin is an indole produced by the pineal gland at night under normal light or dark conditions, and its levels, which are higher in children than in adults, begin to decrease prior to the onset of puberty and continue to decline thereafter." | 2.66 | New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence. ( Hsieh, YH; Lin, CW; Lu, KH; Reiter, RJ; Su, SC; Yang, SF, 2020) |
| "Melatonin is known to inhibit cell proliferation in both tumor types." | 1.72 | Calcium acts as a central player in melatonin antitumor activity in sarcoma cells. ( Herrera, F; Martín, V; Puente-Moncada, N; Rodríguez, C; Sánchez-Sánchez, AM; Turos-Cabal, M, 2022) |
| " Furthermore, the non-cytolytic and non-cytotoxic metronomic hydroxyurea dosage increased the biological therapy outcome by strengthening antitumor capability." | 1.72 | A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness. ( Borghetto, V; Costanzo, E; Di Bella, G; Di Bella, L; Moscato, I, 2022) |
| "Melatonin treatment significantly downregulated the expression of lncRNA JPX in Saos-2, MG63 and U2OS cells." | 1.62 | Anticancer effects of melatonin via regulating lncRNA JPX-Wnt/β-catenin signalling pathway in human osteosarcoma cells. ( Du, J; Li, B; Li, Y; Zou, J, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 12 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| MacDonald, IJ | 1 |
| Tsai, HC | 1 |
| Chang, AC | 2 |
| Huang, CC | 1 |
| Yang, SF | 5 |
| Tang, CH | 2 |
| Li, Y | 2 |
| Zou, J | 1 |
| Li, B | 1 |
| Du, J | 1 |
| Sánchez-Sánchez, AM | 1 |
| Turos-Cabal, M | 1 |
| Puente-Moncada, N | 1 |
| Herrera, F | 1 |
| Rodríguez, C | 1 |
| Martín, V | 1 |
| Hosseini, F | 1 |
| Shanehbandi, D | 1 |
| Soleimanpour, J | 1 |
| Yousefi, B | 2 |
| Alemi, F | 1 |
| Dana, PM | 1 |
| Sadoughi, F | 1 |
| Reiter, RJ | 4 |
| Asemi, Z | 1 |
| Yang, C | 1 |
| Kang, F | 1 |
| Huang, X | 1 |
| Zhang, W | 1 |
| Wang, S | 1 |
| Han, M | 1 |
| Zhang, Z | 1 |
| Li, J | 1 |
| Di Bella, G | 1 |
| Di Bella, L | 1 |
| Borghetto, V | 1 |
| Moscato, I | 1 |
| Costanzo, E | 1 |
| Huang, W | 1 |
| Wu, X | 1 |
| Zhao, Y | 1 |
| Liu, Y | 1 |
| Zhang, B | 1 |
| Qiao, M | 1 |
| Zhu, Z | 1 |
| Zhao, Z | 1 |
| Lu, KH | 3 |
| Lin, RC | 1 |
| Yang, JS | 1 |
| Yang, WE | 1 |
| Lin, CW | 2 |
| Hsieh, YH | 2 |
| Su, SC | 2 |
| Vimalraj, S | 1 |
| Saravanan, S | 1 |
| Raghunandhakumar, S | 1 |
| Anuradha, D | 1 |
| Liu, PI | 1 |
| Lai, JL | 1 |
| Lin, TH | 1 |
| Tsai, CH | 1 |
| Chen, PC | 1 |
| Jiang, YJ | 1 |
| Lin, LW | 1 |
| Huang, WC | 1 |
| Lin, YC | 1 |
| Chien, MH | 1 |
| Liu, L | 1 |
| Wang, T | 1 |
| Yang, X | 1 |
| Xu, C | 1 |
| Liao, Z | 1 |
| Wang, X | 1 |
| Su, D | 1 |
| Zhou, H | 1 |
| Qiu, X | 1 |
| Chen, Y | 1 |
| Huang, D | 1 |
| Lian, C | 1 |
| Su, P | 1 |
| Wang, YP | 1 |
| Yang, ZP | 1 |
| Altındal, DÇ | 1 |
| Gümüşderelioğlu, M | 1 |
| Lissoni, P | 2 |
| Cazzaniga, M | 1 |
| Tancini, G | 1 |
| Scardino, E | 1 |
| Musci, R | 1 |
| Barni, S | 1 |
| Maffezzini, M | 1 |
| Meroni, T | 1 |
| Rocco, F | 1 |
| Conti, A | 2 |
| Maestroni, G | 1 |
| Panzer, A | 1 |
| Rovelli, F | 1 |
| Malugani, F | 1 |
| Bucovec, R | 1 |
| Maestroni, GJ | 1 |
| Starr, KW | 1 |
5 reviews available for melatonin and Bone Cancer
| Article | Year |
|---|---|
Melatonin Inhibits Osteoclastogenesis and Osteolytic Bone Metastasis: Implications for Osteoporosis.
Topics: Animals; Antioxidants; Bone Neoplasms; Humans; Melatonin; Osteoclasts; Osteogenesis; Osteoporosis | 2021 |
Potential Mechanisms of Melatonin in Osteosarcoma and Bone-Related Neoplasms: Updated Review.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Melatonin; Osteosarcoma; Sarcoma, Ewing | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Molecular and Cellular Mechanisms of Melatonin in Osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Drug | 2019 |
New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence.
Topics: Adolescent; Animals; Bone Neoplasms; Child; Humans; Melatonin; Muscle Neoplasms; Neoplasm Invasivene | 2020 |
2 trials available for melatonin and Bone Cancer
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Anti-angiogenic activity of melatonin in advanced cancer patients.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; C | 2001 |
15 other studies available for melatonin and Bone Cancer
| Article | Year |
|---|---|
Anticancer effects of melatonin via regulating lncRNA JPX-Wnt/β-catenin signalling pathway in human osteosarcoma cells.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Exp | 2021 |
Calcium acts as a central player in melatonin antitumor activity in sarcoma cells.
Topics: Bone Neoplasms; Calcium; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal | 2022 |
Melatonin Increases the Sensitivity of Osteosarcoma Cells to Chemotherapy Drug Cisplatin.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplas | 2022 |
Melatonin attenuates bone cancer pain via the SIRT1/HMGB1 pathway.
Topics: Analgesics; Animals; Bone Neoplasms; Cancer Pain; Cytokines; HMGB1 Protein; Interleukin-6; Male; Mel | 2022 |
A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness.
Topics: Antioxidants; Bone Neoplasms; Butyric Acid; Humans; Hydroxyurea; Melatonin; Osteosarcoma; Tretinoin | 2022 |
Janus-Inspired Core-Shell Structure Hydrogel Programmatically Releases Melatonin for Reconstruction of Postoperative Bone Tumor.
Topics: Bone Neoplasms; Bone Regeneration; Humans; Hydrogels; Melatonin; Osteogenesis; Tissue Scaffolds | 2023 |
Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma.
Topics: Angiogenesis Inhibitors; Animals; Bone Neoplasms; Cell Line, Tumor; Chickens; Egg Yolk; Endothelial | 2020 |
Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases.
Topics: Animals; Bone Marrow Cells; Bone Neoplasms; Bone Resorption; Cell Differentiation; Disease Models, A | 2021 |
Melatonin attenuates osteosarcoma cell invasion by suppression of C-C motif chemokine ligand 24 through inhibition of the c-Jun N-terminal kinase pathway.
Topics: Adolescent; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Chemokine CCL24; Female; Humans; Melato | 2018 |
MTNR1B loss promotes chordoma recurrence by abrogating melatonin-mediated β-catenin signaling repression.
Topics: Animals; beta Catenin; Biomarkers, Tumor; Bone Neoplasms; Cell Line, Tumor; Chondroma; Female; Human | 2019 |
Effects of melatonin combined with Cis-platinum or methotrexate on the proliferation of osteosarcoma cell line SaOS-2.
Topics: Apoptosis; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Flow Cytomet | 2015 |
Melatonin releasing PLGA micro/nanoparticles and their effect on osteosarcoma cells.
Topics: Bone Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Humans; Lactic Acid; Melatonin; Nanop | 2016 |
Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combi | 1997 |
Melatonin in osteosarcoma: an effective drug?
Topics: Adolescent; Antineoplastic Agents; Bone Development; Bone Neoplasms; Child; Drug Therapy, Combinatio | 1997 |
Hormonal imbalance and the sarcomata.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Age Factors; Aged; Bone Neoplasms; Child, Preschool; | 1969 |